Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 3, 2009

Nycomed Pads European Business with Acquisition of Generics from Sanofi-Aventis and Zentiva

  • Nycomed is beefing up its business in Central and Eastern Europe through the purchase of 20 branded generic products from Sanofi-Aventis and Zentiva. The acquired portfolio has annual revenues of approximately €17million, or $24.33 million, in these regions according to Nycomed.

    Nycomed has the right to sell the drugs in the Czech Republic, Slovakia, Romania, Hungary, Estonia, and Bulgaria. The company will also take over production in the coming years.

    Among the acquired products is Zentiva's hypnotic, Hypnogen, which is marketed in the Czech Republic, Slovak Republic, and Estonia. Also, in the Czech Republic the deal comprises a strong franchise of betablockers (Vasocardin, Betaxa, and Tenoloc), points out Nycomed. This strengthens the company’s cardiovascular business around Ebrantil.

    Nycomed is a privately owned pharmaceutical company with a portfolio covering branded medicines in gastroenterology, respiratory and inflammatory diseases, pain, osteoporosis, as well as tissue management. It also has a range of OTC products. Headquartered in Zurich, the firm generated total sales of €3.4 billion, or $4.87 million, in 2008.

     



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »